Keith A. Goldan - 13 Jun 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Financial Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
13 Jun 2022
Net transactions value
+$3,588,000
Form type
4
Filing time
15 Jun 2022, 16:12:27 UTC
Previous filing
17 Mar 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Award $0 +3,205 $0.000000 3,205 13 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $3,588,000 +230,000 $15.60 230,000 13 Jun 2022 Common Stock 230,000 $15.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock Units that vest 50% of the shares on June 13, 2023 and the remaining 50% of the shares on June 13, 2024.
F2 Twenty five percent (25%) of the total number of shares underlying the option shall vest on June 13, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.